EA201590730A1 - Способ и стероидная композиция для местного применения - Google Patents

Способ и стероидная композиция для местного применения

Info

Publication number
EA201590730A1
EA201590730A1 EA201590730A EA201590730A EA201590730A1 EA 201590730 A1 EA201590730 A1 EA 201590730A1 EA 201590730 A EA201590730 A EA 201590730A EA 201590730 A EA201590730 A EA 201590730A EA 201590730 A1 EA201590730 A1 EA 201590730A1
Authority
EA
Eurasian Patent Office
Prior art keywords
fatty alcohol
pharmaceutically acceptable
local application
halobetazole
corticosteroid
Prior art date
Application number
EA201590730A
Other languages
English (en)
Other versions
EA029494B1 (ru
Inventor
Кейт А. Джонсон
Карл Ф. Попп
Original Assignee
Майкэл Фармасьютикалз Ллс - Х Сиэриз
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50485547&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201590730(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Майкэл Фармасьютикалз Ллс - Х Сиэриз filed Critical Майкэл Фармасьютикалз Ллс - Х Сиэриз
Publication of EA201590730A1 publication Critical patent/EA201590730A1/ru
Publication of EA029494B1 publication Critical patent/EA029494B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

В изобретении предложены стабильные при хранении местные композиции на основе лосьонов для лечения дерматозов, отвечающих на кортикостероиды, которые включают галобетазоловый материал, содержащий галобетазол или его фармацевтически приемлемые соли, сложные эфиры и сольваты; и фармацевтически приемлемый носитель, который включает (а) один или более жирный спирт и/или один или более чем один алкоксилированный жирный спирт, (b) один или более полиоловый увлажнитель и (с) диизопропиладипат. В данном изобретении предложены стабильные при хранении местные композиции на основе лосьонов для лечения дерматозов, отвечающих на кортикостероиды, которые включают 0,05% галобетазола пропионата; и фармацевтически приемлемый носитель, который включает (а) один или более жирный спирт и/или один или более алкоксилированный жирный спирт, (b) один или более полиоловый увлажнитель и (с) диизопропиладипат.
EA201590730A 2012-10-18 2013-10-16 Способ и стероидная композиция для местного применения EA029494B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261715467P 2012-10-18 2012-10-18
US13/921,833 US8962028B2 (en) 2012-10-18 2013-06-19 Topical steroid composition and method
US13/921,859 US20140112959A1 (en) 2012-10-18 2013-06-19 Topical steroid composition and method
PCT/US2013/065266 WO2014062817A1 (en) 2012-10-18 2013-10-16 Topical steroid composition and method

Publications (2)

Publication Number Publication Date
EA201590730A1 true EA201590730A1 (ru) 2015-08-31
EA029494B1 EA029494B1 (ru) 2018-04-30

Family

ID=50485547

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590730A EA029494B1 (ru) 2012-10-18 2013-10-16 Способ и стероидная композиция для местного применения

Country Status (20)

Country Link
US (3) US8962028B2 (ru)
EP (1) EP2919753A1 (ru)
JP (1) JP6385938B2 (ru)
KR (1) KR101832041B1 (ru)
CN (1) CN104884043B (ru)
AP (1) AP2015008420A0 (ru)
AU (1) AU2013331271B2 (ru)
BR (1) BR112015008951A2 (ru)
CA (1) CA2888853C (ru)
EA (1) EA029494B1 (ru)
HK (1) HK1214154A1 (ru)
IN (1) IN2015DN04160A (ru)
MX (1) MX371362B (ru)
MY (1) MY179354A (ru)
NZ (1) NZ706918A (ru)
PH (1) PH12015500859B1 (ru)
SG (1) SG11201502931YA (ru)
UA (1) UA115073C2 (ru)
WO (1) WO2014062817A1 (ru)
ZA (1) ZA201502692B (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8809307B2 (en) 2010-11-22 2014-08-19 Dow Pharmaceutical Sciences, Inc. Pharmaceutical formulations containing corticosteroids for topical administration
US11957753B2 (en) 2010-11-22 2024-04-16 Bausch Health Ireland Limited Pharmaceutical formulations containing corticosteroids for topical administration
WO2016205001A1 (en) 2015-06-18 2016-12-22 Valeant Pharmaceuticals North America Topical compositions comprising a corticosteroid and a retinoid for treating psoriasis
US20210161870A1 (en) 2017-06-07 2021-06-03 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US12042487B2 (en) 2018-11-16 2024-07-23 Arcutis Biotherapeutics, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US20200155524A1 (en) 2018-11-16 2020-05-21 Arcutis, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US12011437B1 (en) 2017-06-07 2024-06-18 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
WO2018236803A1 (en) 2017-06-19 2018-12-27 Novan, Inc. TOPICAL COMPOSITIONS AND METHODS OF USE
KR20210044191A (ko) 2018-06-04 2021-04-22 아큐티스, 인크. 로플루밀라스트 피부 침투 지연 시간의 개선 방법 및 제형
US10945952B2 (en) 2019-03-14 2021-03-16 Crescita Therapeutics Inc. Rinse-off compositions and uses thereof for delivery of active agents
CN109833291B (zh) * 2019-04-03 2022-08-26 普霖贝利生物医药研发(上海)有限公司 一种稳定的丙酸氯倍他索软膏及其制备方法
WO2024072942A2 (en) 2022-09-29 2024-04-04 Adora Animal Health Corporation Skin penetrating formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2655570A1 (de) 1975-12-12 1977-06-16 Ciba Geigy Ag Neue polyhalogensteroide und verfahren zu ihrer herstellung
DE3225848A1 (de) * 1982-07-07 1984-01-19 Schering AG, 1000 Berlin und 4709 Bergkamen Kortikoidhaltige zubereitung zur topischen applikation
US5064655A (en) 1989-02-24 1991-11-12 Liposome Technology, Inc. Liposome gel composition and method
US5219877A (en) 1989-09-25 1993-06-15 Bristol-Myers Squibb Company Lauryl alcohol as skin penetration enhancer for topical imidazole agents
US5326566A (en) 1991-05-17 1994-07-05 Bristol-Myers Squibb Company Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
TW218849B (ru) * 1991-05-17 1994-01-11 Bristol Myers Squibb Co
CA2143515A1 (en) 1994-03-22 1995-09-23 Prakash Parab Method for enhancing the rate of skin permeation of lactic acid through use of the l-enantiomer
US6647058B1 (en) 1997-06-23 2003-11-11 Paradyne Corporation Performance customization system and process for optimizing XDSL performance
US6171985B1 (en) 1997-12-01 2001-01-09 3M Innovative Properties Company Low trauma adhesive article
US6673374B2 (en) 1998-07-31 2004-01-06 Howard Murad Pharmaceutical compositions and methods for managing skin conditions
US6315980B1 (en) 1998-09-25 2001-11-13 Shiseido Company, Ltd. Skin barrier function recovery and promotion composition and evaluation method thereof
AU1803100A (en) * 1999-01-06 2000-07-24 Taisho Pharmaceutical Co., Ltd. Amelometasone lotion
US6495126B1 (en) 1999-07-20 2002-12-17 Mary Kay Inc. Treatment and composition for achieving skin anti-aging benefits by corneum protease activation
US6479058B1 (en) * 1999-09-02 2002-11-12 Mccadden Michael E. Composition for the topical treatment of poison ivy and other forms of contact dermatitis
US6656928B1 (en) 1999-09-02 2003-12-02 Mccadden Michael E. Composition for the topical treatment of rashes, dermatoses and lesions
US6967023B1 (en) 2000-01-10 2005-11-22 Foamix, Ltd. Pharmaceutical and cosmetic carrier or composition for topical application
US6756032B1 (en) 2000-07-12 2004-06-29 The Procter & Gamble Company Method to enhance and/or prolong the effects of a primary challenge to a responsive system with a secondary challenge
US6387383B1 (en) * 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
US6790203B2 (en) 2000-12-20 2004-09-14 Sca Hygiene Products Ab Absorbent product comprising leakage barriers
US6830758B2 (en) 2001-04-02 2004-12-14 Lectec Corporation Psoriasis patch
US6781027B2 (en) 2001-12-14 2004-08-24 Kimberly-Clark Worldwide, Inc. Mixed denier fluid management layers
US6765001B2 (en) * 2001-12-21 2004-07-20 Medicis Pharmaceutical Corporation Compositions and methods for enhancing corticosteroid delivery
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US7208485B2 (en) 2003-01-13 2007-04-24 Chemagis Ltd. Crystalline forms of halobetasol propionate
US7186416B2 (en) 2003-05-28 2007-03-06 Stiefel Laboratories, Inc. Foamable pharmaceutical compositions and methods for treating a disorder
US8016811B2 (en) 2003-10-24 2011-09-13 Altea Therapeutics Corporation Method for transdermal delivery of permeant substances
WO2005065185A2 (en) * 2003-12-24 2005-07-21 Collegium Pharmaceuticals, Inc. Temperature-stable formulations, and methods of development thereof
AU2005213895A1 (en) 2004-02-19 2005-09-01 Chemaphor Inc. Topical formulations for the treatment of skin conditions
US20070196457A1 (en) 2004-06-07 2007-08-23 Jie Zhang Two or more volatile solvent-containing compositions and methods for dermal delivery of drugs
US20070189980A1 (en) 2004-06-07 2007-08-16 Jie Zhang Compositions and methods for treating alopecia
US8741333B2 (en) 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for treating dermatitis or psoriasis
DK2377546T3 (en) 2004-12-21 2017-02-13 Musc Found For Res Dev Compositions and Methods to Promote Wound Healing and Tissue Regeneration
US20070167420A1 (en) * 2005-04-07 2007-07-19 Daniella Gutman Process for preparing a crystalline form of halobetasol propionate
DE202008018063U1 (de) 2007-04-25 2011-10-11 Teva Pharmaceutical Industries Ltd. Pharmazeutischer Hilfsstoffkomplex
RU2470645C2 (ru) * 2007-09-10 2012-12-27 Гленмарк Фармасьютикалс Лимитед Фармацевтическая композиция для местного применения, содержащая комбинацию фузидовой кислоты и кортикостероида
CH701253A1 (de) 2009-06-12 2010-12-15 Mibelle Ag Verwendung eines Extraktes aus Schneealgen in kosmetischen oder dermatologischen Formulierungen.
US8809307B2 (en) * 2010-11-22 2014-08-19 Dow Pharmaceutical Sciences, Inc. Pharmaceutical formulations containing corticosteroids for topical administration

Also Published As

Publication number Publication date
HK1214154A1 (zh) 2016-07-22
MX371362B (es) 2020-01-27
US20140112959A1 (en) 2014-04-24
WO2014062817A1 (en) 2014-04-24
US8962028B2 (en) 2015-02-24
EP2919753A1 (en) 2015-09-23
KR101832041B1 (ko) 2018-02-23
SG11201502931YA (en) 2015-05-28
MX2015004863A (es) 2016-02-05
IN2015DN04160A (ru) 2015-10-16
AP2015008420A0 (en) 2015-05-31
MY179354A (en) 2020-11-04
NZ706918A (en) 2019-01-25
CN104884043B (zh) 2018-12-11
CA2888853A1 (en) 2014-04-24
PH12015500859A1 (en) 2015-06-22
CN104884043A (zh) 2015-09-02
BR112015008951A2 (pt) 2017-07-04
AU2013331271B2 (en) 2017-09-28
ZA201502692B (en) 2016-01-27
US20140112991A1 (en) 2014-04-24
US20150119827A1 (en) 2015-04-30
KR20150069005A (ko) 2015-06-22
EA029494B1 (ru) 2018-04-30
AU2013331271A1 (en) 2015-05-07
JP2015534980A (ja) 2015-12-07
UA115073C2 (uk) 2017-09-11
PH12015500859B1 (en) 2015-06-22
JP6385938B2 (ja) 2018-09-05
CA2888853C (en) 2019-02-12

Similar Documents

Publication Publication Date Title
EA201590730A1 (ru) Способ и стероидная композиция для местного применения
BR112016029338A2 (pt) creme transdérmico
BR112016029241A2 (pt) método para tratamento dos cabelos com um condicionador concentrado
CL2019000586A1 (es) Composiciones de toxinas clostridiales no proteicas.
AR102198A1 (es) Proceso para reducir partículas subvisibles en una formulación farmacéutica
CY1120888T1 (el) Διαδερμικες φαρμακευτικες συνθεσεις περιλαμβανοντας ενεργους παραγοντες
MX2017004896A (es) Uso de hexadeca-8, 15-dienal como producto quimico aromatico.
BR112018013192A2 (pt) composição e método para crescimento de cabelos
NI201700100A (es) Composiciones farmacéuticas para terapia combinada
CL2017000820A1 (es) Compuestos de aminopurina sustituida, composiciones de los mismos, y metodos de tratamiento con los mismos
CL2017001139A1 (es) Composiciones de antibiótico
BR112016029264A2 (pt) método para tratamento dos cabelos com um condicionador concentrado
IN2015DN01442A (ru)
CL2011002091A1 (es) Preparacion que comprende: a. 0,01-5,0% de povidona yodada y b. 0,01-2,0% de un esteroide seleccionado entre loteprednol y rimexolona, sus esteres o sales de ello; util para tratar otitis.
TR201908003T4 (tr) TLR4 agonistleri içeren gelişmiş adjuvan formülasyonları ve bunların kullanım metotları.
BR112016030835B8 (pt) Composição para crescimento de cabelos contendo minoxidil
IN2015DN01547A (ru)
EA201692334A1 (ru) Кортикостероидные композиции для местного применения
BR112019024566A2 (pt) inibidores de pirazol magl
BR112013004493A2 (pt) método para produzir um produto agrícola, uso de uma composição, e método para aumentar a eficácia de um produto químico agrícola.
BR112012032248A2 (pt) composições de 5-etil-2-{4-[-4(-4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina
EP3197498A4 (en) Compositions containing ambient-temperature stable, inactivated but therapeutically active biopharmaceuticals&methods for formulation thereof
MX2016015211A (es) Formulaciones topicas y usos de las mismas.
MX370990B (es) Ésteres de ácidos oligo-hidroxicarboxílicos y uso de los mismos.
EP3816266A4 (en) SS-HYDROXYISOBUTIC ACID ESTER COMPOUND, PERFUME COMPOSITION AND USE AS A PERFUME